AUTHORS
Talha Badar, MD, Mahesh Kumar, MD2, Kendall Diebold, CNP, MSN3, Omer Jamy, MD4, Alexander Coltoff, MD5, Julian Guetta-Weiss, MD6, Chenyu Lin, MD7, Jessica Yamada8, Anand Ashwin Patel, MD9, Jennifer Jiang, M.D.10, Yao-Shan Fan, M.D., Ph.D.11, Terra Lasho, PhD12, Timothy Chlon, PhD13, Abhishek Avinash Mangaonkar, MBBS14, Cecilia Arana Yi, M.D.15, Rong He, MD16, David Viswanatha, MD17, Alejandro Ferrer, PhD18, Antoine N. Saliba, M.D.19, Yael Kusne, MD, PhD20, Tariq Kewan, MD21, Mark R. Litzow, MD22, Naseema Gangat, MBBS23, Aref Al-Kali, M.D.24, Hemant Murthy, MD25, Mohamed Kharfan-Dabaja, MD26, James Foran, FRCPC27, Mrinal M. Patnaik, MD, MBBS28
AFFILIATIONS
1 Mayo Clinic, Jacksonville, Florida, United States
2 Mayo Clinic, Jacksonville, Florida, United States
3 University of Albama at Birmingham, Birmingham, Alabama, United States
4 University of Albama at Birmingham, Birmingham, Alabama, United States
5 Medical University of South Carolina, Charleston, South Carolina, United States
6 Duke University, Durham, North Carolina, United States
7 Duke University, Durham, North Carolina, United States
8 University of Chicago, Chicago, Illinois, United States
9 University of Chicago, Chicago, Illinois, United States
10 Mayo Clinic, Jacksonville, Florida, United States
11 Mayo Clinic, Jacksonville, Florida, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Cincinnati Children's Hospital, Cincinnati, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Phoenix, Arizona, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Phoenix, Arizona, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Rochester, Minnesota, United States
24 Mayo Clinic, Rochester, Minnesota, United States
25 Mayo Clinic, Jacksonville, Florida, United States
26 Mayo Clinic, Jacksonville, Florida, United States
27 Mayo Clinic, Jacksonville, Florida, United States
28 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background: Germline DDX41 mutations define a distinct molecular subgroup of myeloid neoplasms (MN) associated with favorable outcomes. The clinical and genomic significance of concurrent TP53 mutations remains poorly characterized. We evaluated whether concurrent TP53 mutations alter the favorable biology of germline DDX41-mutated (mt) MN.
Methods: Among 300 patients with germline DDX41mt MDS or AML from a multicenter consortium (including clonal hematopoiesis/CCUS), 176 had MN (MDS-IB1, MDS-IB2, or AML); 19 (11%) of these had somatic TP53 mutations. We first compared baseline clinicogenomic characteristics and responses to therapy between DDX41mt/TP53mt (n=19) and DDX41mt/TP53 wild-type (wt) (n=157) MN patients. To reduce heterogeneity, duration of response (DOR) and overall survival (OS) analyses within this comparison were restricted to patients with bone marrow (BM) blasts ≥10% (MDS-IB2/AML; DDX41mt/TP53mt n=17, DDX41mt/TP53wt n=115). We then generated a 1:2 propensity score-matched (PSM) cohort of 19 DDX41mt/TP53mt and 38 DDX41wt/TP53mt patients, similarly, restricting DOR/OS analyses to BM blasts ≥10% (n=17 vs 32), to evaluate whether the DDX41mt background modifies outcomes.
Results: Among the 19 DDX41mt/TP53mt patients, median age was 67 years (IQR, 60.0–73.5), 74% were male, and 79% had AML. The most frequent germline DDX41 variants were D140Gfs* (26%) and p.M1I (11%), and 58% had a somatic second DDX41 hit, uniformly R525H (100%). Overall response rate to any form of therapy (ORR [CR/CRh/PR]) was 58% (CR/CRh 53%), while 26% underwent alloHCT.
Compared with DDX41mt/TP53wt patients (n=157), DDX41mt/TP53mt patients had a higher somatic co-mutation burden (89% vs 50% with ≥ 1 co-mutation; P=0.001), higher BM blast % (25.0% vs 18.0%; P=0.020), with complex karyotypes being more frequent (32% vs 1%; P<0.001). The median age, DDX41 variant type, and somatic second-hit mutational rates were similar. Treatment types did not differ significantly (HMA 11% vs 31%, HMA+venetoclax 37% vs 40%, intensive chemotherapy 37% vs 22%, best supportive care/others 16% vs 7%; P=0.133), as did the ORR (58% vs 66%; P=0.506) and alloHCT utilization (26% vs 29%; P=0.787) rates, between the two groups. In the BM blast ≥10% subgroup, while the median DOR was numerically shorter in DDX41mt/TP53mt patients (15.5 vs 23.1 months; 95% CI, 0.96–5.00; P=0.054), the median OS was significantly shorter in DDX41mt/TP53mt patients (26.9 vs 56.7 months; 95% CI, 1.79–6.25; P<0.001), an association that persisted after censoring at alloHCT (26.9 vs 39.9 months; HR, 3.13; 95% CI, 1.54–6.25; P<0.001).
After propensity matching, DDX41mt/TP53mt and DDX41wt/TP53mt groups were balanced for disease category, age, blast percentage, and co-occurring mutations (splicing factor, TET2, ASXL1, DNMT3A; all P>0.99), as well as treatment types (P=0.802) and alloHCT utilization (26% vs 26%; P>0.99). DDX41mt/TP53mt patients had a lower prevalence of complex karyotypes (32% vs 76%; P=0.016) and more likely to be diploid (42% vs 11%). Median TP53 VAF was comparable between the two groups (18.0% vs 23.5%; P=0.067), as were the types of therapies used (HMA 11% vs 11%, HMA+venetoclax 37% vs 53%, intensive chemotherapy 37% vs 26%, best supportive care 11% vs 5%, others 5% vs 5%; P=0.802). The ORR were also similar (58% vs 45%; P=0.349). In the BM blast ≥10% subgroup, median DOR was numerically better (15.5 vs 6.7 months; HR, 0.84; 95% CI, 0.33–2.13; P=0.727), without statistical significance. The median OS was also not different (26.9 vs 6.6 months; HR, 0.79; 95% CI, 0.41–1.54; P=0.48) between the two groups, even after censoring at alloHCT (26.9 vs 6.5 months; HR, 0.56; 95% CI, 0.26–1.21; P=0.13).
Conclusion: Concurrent TP53 mutations identify a higher-risk subset of germline DDX41-mt MN characterized by increased genomic complexity and significantly inferior survival. Despite this adverse impact, DDX41/TP53 co-mt disease retains a distinct genomic profile compared with propensity-matched TP53-mt MN lacking germline DDX41-mt, with fewer complex cytogenetic abnormalities and numerically improved outcomes. These findings suggest that germline DDX41-mt potentially alter the biology of TP53-mt MN, although confirmation in larger cohorts is needed.
DISCLOSURES
Talha Badar, MD: Syndax - Honoraria; Takeda - Honoraria; Ascentage - Honoraria; Geron - Honoraria; Amgen - Honoraria; Takeda - Research Funding; Amgen - Research Funding